Given that c-Myc may serve as one of the candidate targets of cancer therapy (58, 59), future studies on how AsIII in combination with gamabufotalin affects the c-Myc expression profile in a mouse xenograft model of human glioblastoma are warranted. The gene discussed is MYC; the disease is glioblastoma.